Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Rating of “Moderate Buy” by Analysts
Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target […]
More Stories
Varex Imaging (NASDAQ:VREX) Updates Q1 2025 Earnings Guidance
Varex Imaging (NASDAQ:VREX – Get Free Report) issued an update on its first quarter 2025 earnings guidance on Tuesday morning....
Datadog, Inc. (NASDAQ:DDOG) President Amit Agarwal Sells 150,000 Shares
Datadog, Inc. (NASDAQ:DDOG – Get Free Report) President Amit Agarwal sold 150,000 shares of the business’s stock in a transaction...
Cameco Co. (TSE:CCO) Senior Officer Sells C$1,124,678.76 in Stock
Cameco Co. (TSE:CCO – Get Free Report) (NYSE:CCJ) Senior Officer Brian Arthur Reilly sold 14,062 shares of the business’s stock...
Dimensional Global Credit ETF Declares Dividend of $0.54 (NASDAQ:DGCB)
Dimensional Global Credit ETF (NASDAQ:DGCB – Get Free Report) announced a dividend on Monday, November 18th,NASDAQ Dividends reports. Shareholders of...
Expensify, Inc. (NASDAQ:EXFY) CEO David Michael Barrett Sells 45,094 Shares
Expensify, Inc. (NASDAQ:EXFY – Get Free Report) CEO David Michael Barrett sold 45,094 shares of the firm’s stock in a...
Alan B. Cardenas Sells 6,102 Shares of Coursera, Inc. (NYSE:COUR) Stock
Coursera, Inc. (NYSE:COUR – Get Free Report) SVP Alan B. Cardenas sold 6,102 shares of Coursera stock in a transaction...